Cargando…
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
BACKGROUND: Breast cancer stem cells (BCSCs) have been suggested to have clinical implications for cancer therapeutics because of their proposed role in chemoresistance. The aim of this study was to investigate the impact of BCSC marker expression on clinical outcome and trastuzumab response in huma...
Autores principales: | Seo, An Na, Lee, Hee Jin, Kim, Eun Joo, Jang, Min Hye, Kim, Yu Jung, Kim, Jee Hyun, Kim, Sung-Won, Ryu, Han Suk, Park, In Ae, Im, Seock-Ah, Gong, Gyungyub, Jung, Kyung Hae, Kim, Hee Jeong, Park, So Yeon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865964/ https://www.ncbi.nlm.nih.gov/pubmed/27115469 http://dx.doi.org/10.1038/bjc.2016.101 |
Ejemplares similares
-
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015) -
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014) -
Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009) -
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
por: Lee, H E, et al.
Publicado: (2011) -
Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)